肌少症与肝细胞癌的临床研究进展  

Research progress of sarcopenia and hepatocellular carcinoma

作　　者：刘建营 常静[2] Jianying Liu;Jing Chang(Department of Radiology,The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences),Jinan 250031,China;Department of the Seventh Internal Medicine,The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences),Jinan 250031,China)

机构地区：[1]山东第一医科大学第三附属医院(山东省医学科学院附属医院)放射科 [2]山东第一医科大学第三附属医院(山东省医学科学院附属医院)内七科

出　　处：《中国肿瘤临床》2020年第17期897-901,共5页Chinese Journal of Clinical Oncology

基　　金：国家重点研发计划资助项目(编号:2018YFC2002000)资助。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)是中国发病率及死亡率均较高的一种恶性肿瘤。肌少症(sarcopenia,SAR)在多种恶性肿瘤中的发病率均较高,且伴随更高的治疗不良反应率及更差的预后。HCC的发生发展和预后、对各种治疗的不良反应均与肌少症密切相关。本文就国内外关于HCC和肌少症间的相关研究进行综述,以寻找两者之间的关系,指导临床治疗。Hepatocellular carcinoma(HCC)is a malignant tumor associated with high morbidity and mortality in China.The incidence of sarcopenia(SAR)in patients with various malignant tumors is relatively high,and it is accompanied by great severity of treatment toxicity and poor prognosis.The occurrence,development,and prognosis of HCC and adverse reactions to various treatments are closely associated with SAR.Here,we review the researches on HCC and SAR in China and abroad to clarify the relationship and subsequently provide reference for clinical treatment.

关 键 词：肝细胞癌 肌少症 治疗 

分 类 号：R685[医药卫生—骨科学] R735.7[医药卫生—外科学]